<qa>  What is the EVEREST II Randomized Controlled Trial?EVEREST II Randomized Controlled Trial RCT is a prospective, multi-center, randomized study of the MitraClip System in the treatment of mitral valve regurgitation, randomizing patients to MitraClip or mitral valve surgery. The EVEREST II High Risk Registry HRR study is a prospective multi-center study of the MitraClip System for the treatment of mitral valve regurgitation in high surgical risk patients. Enrollment in the RCT and HRR is closed. A continued access prospective, multi-center study REALISM of the MitraClip System in a surgical population non-high risk arm and a high surgical risk population high risk arm is ongoing. Enrollment in the non-high risk arm of REALISM is closed. Enrollment in the high risk arm of REALISM is ongoing. Patients enrolled in EVEREST II undergo 30-day, 6-month, 12-month, 18-month and 24-month clinical and echocardiographic follow-up, and then annually for 5 years. 